UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 5, 2014

TherapeuticsMD, Inc.
(Exact Name of Registrant as Specified in its Charter)

Nevada	**000-16731**	**87-0233535**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6800 Broken Sound Parkway NW, Third Floor
Boca Raton, FL 33487
(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (561) 961-1900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

We are furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of the textual information from a PowerPoint presentation to be given at meetings with institutional investors or analysts. This information may be amended or updated at any time and from time to time through another Form 8-K, a later company filing, or other means. The PowerPoint presentation attached as Exhibit 99.1 to this Current Report on Form 8-K updates and replaces in its entirety all prior PowerPoint presentations filed by us.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

The text included with this Report on Form 8-K is available on our website located at *www.therapeuticsmd.com*, although we reserve the right to discontinue that availability at any time.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits.*

Exhibit Number	Description
99.1	TherapeuticsMD, Inc. presentation dated May 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 6, 2014

THERAPEUTICSMD, INC.

By: /s/ *Daniel A. Cartwright*
Name: Daniel A. Cartwright
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	TherapeuticsMD, Inc. presentation dated May 2014.

Exhibit 99.1


TherapeuticsMD®
NYSE MKT: TXMD
Corporate Overview
Q2 - 2014
COPYRIGHT 2014 by TherapeuticsMD – May 2014

Forward-Looking Statements

This presentation includes forward-looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including predictions, estimates, and other information that might be considered forward-looking. While these forward-looking statements represent TherapeuticsMD, Inc.'s ("TherapeuticsMD," "we," "us," and "our") current judgment on what the future holds, they are subject to risks and uncertainties, many of which are outside our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information, future events, or otherwise.

Throughout this presentation, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K filed on March 5, 2014, Forms 10-Q, our Forms 8-K, and our other filings with the Securities and Exchange Commission, for a more complete discussion of these factors and other risks, particularly under the heading "Risk Factors." A PDF copy of our press releases and financial tables can be viewed and downloaded on the TherapeuticsMD website: **www.therapeuticsmd.com/InvestorRelations.aspx.**

TherapeuticsMD Pipeline



TherapeuticsMD

(1) IMS NTRx Prescription Monthly by Source Healthcare Analytics.
(2) Estimates per: Dr. Lloyd Mencer Jr., Editor-in-Chief, International Journal of Pharmaceutical Compounding; Tom Murry, Executive Director of the Pharmaceutical Compounding Accreditation Board; and Wolf Utian, Consultant for Gynecology and Women's Health at The Cleveland Clinic and Executive Director Emeritus and Honorary Founding President of The North American Menopause Society ("NAMS").
(3) Estimated U.S. sales

TherapeuticsMD Core Development Metrics

1. **Compounds**
   - Well-known chemical entities with defined safety and efficacy therapeutic thresholds

2. **Regulatory Pathway**
   - 505(b)(2) offering more defined, shorter pathway with less efficacy risk than NCE pathway
   - Clear FDA draft guidance requirements for single Phase 3 study

3. **Market**
   - Large, underserved, and growing markets with unique dynamics
   - Favorable payor dynamics

TherapeuticsMD®

Combination Product
TX 001-HR E+P

History of Hormone Therapy

Women's Health Initiative (WHI)

- Hormone Therapy is linked to Cardiovascular, Cancer and other risks
- Estrogen + ***Progestin*** (Prempro) arm had a 24% increase in breast cancer vs. Estrogen alone

TherapeuticsMD

(1) PHAST Prescription Monthly by Source Healthcare Analytics. Inflation Adjusted Number*
(2) Estimates per: Dr. Loyd Allen Jr., Editor-in-Chief, the International Journal of Pharmaceutical Compounding; Tom Murry, Executive Director of the Pharmaceutical Compounding Accreditation Board; and Wulf Utian, Consultant on Gynecology and Women's Health at The Cleveland Clinic and Executive Director Emeritus and Honorary Founding President of The North American Menopause Society ("NAMS").

History of Compounding

Market Shift to Bio-identical Hormone Replacement (BHRT)



TherapeuticsMD

Understanding the Total Menopause Hormone Market



24,000 Specialists in United States

- Both traditional medicine and so-called anti-aging/wellness are targeting the same biologic processes in women - menopause.

TherapeuticsMD

(1) PHAST Prescription Monthly by Source Healthcare Analytics.
(2) Estimates per: Dr. Loyd Allen Jr., Editor-in-Chief, International Journal of Pharmaceutical Compounding; [illegible], Executive Director of the Pharmaceutical Compounding Accreditation Board; and Wulf Utian, Consultant in Gynecology and Women's Health at The Cleveland Clinic and Executive Director Emeritus and Honorary Founding President of The North American Menopause Society ("NAMS").
(3) Symphony Health Report

Rationale for Market Growth:
Bio-identical Progesterone vs. Non-Bioidentical Progestin

Side Effect [1]	Bio-identical Natural Progesterone	Non-Bioidentical Progestins (MPA, NETA, drosperinone)
Breast cancer	More favorable profile (E3N-EPIC study)	Increased risk
Cardiovascular	More favorable profile (PEPI trial)	Increased risk of MI, stroke, VTE
Lipid profile	More favorable profile (PEPI trial)	Less favorable effects on lipid profile (cholesterol, HDL, LDL, triglycerides)
Glucose / insulin	Improved carbohydrate metabolism (PEPI trial)	Deterioration of glucose tolerance or hyperinsulemia or both
Sleep / mood	Improved sleep efficiency [2]	No benefit on sleep properties
Quality of life	Improvement in symptoms and overall satisfaction with bio-identical progesterone HT compared to MPA regimen [3]	

TherapeuticsMD

[1] Alone or in combination with estrogen.
[2] Cauchie, Anne, Rachel Leproult, Mireille L'Hermite-Balé' riaux, Myriam Kerkhofs, and Georges Copinschi. "Progesterone Prevents Sleep Disturbances and Modulates GH, TSH, and Melatonin Secretion in Postmenopausal Women." J Clin Endocrinol Metab 96.4 (2011): 814-23.
[3] Fitzpatrick, Peter, and Wilda. "Comparison of Regimens Containing Oral Micronized Progesterone or Medroxyprogesterone Acetate on Quality of Life in Postmenopausal Women: A Cross-Sectional Survey." J Womens Health Gend Based Med 9.4 (2000): 381-87.

Rationale for Market Growth: Estradiol vs. Conjugated Estrogens

Journal of the American Medical Association September 30, 2013

CEEs (**Premarin**) were associated with a **higher incidence** of **venous thrombosis** and **myocardial infarction** than oral estradiol

Journal of the American Medical Association October 3, 2013

Breast Cancer Risk persists for 13 years after discontinuation of CEE

Menopause September 2013

"**Oral estradiol** may be associated with **a lower risk of stroke** … compared with conventional-dose oral CEE"

TherapeuticsMD

(1) Smith et al. Lower Risk of Cardiovascular Events in Postmenopausal Women Taking Oral Estradiol Compared with Oral Conjugated Equine Estrogens (CEE)
(2) Manson et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials
(3) Shufelt et al. Hormone Therapy Dose, Formulation, Route of Delivery, and Risk of Cardiovascular Events in Women: Findings from the Women's Health Initiative Observational Study

TXMD Novel Drug Design

- **Converted (API) from solid / crystalline to a *New Liquid Drug Form***
  - Estrace (RLD) is a tablet — 0.5 mg, 1.0 mg, and 2.0 mg
  - Prometrium (RLD) is in suspension — 100 mg and 200 mg
- **New solubilized drug form**
  - Achieves FDA requirements of uniformity and stability
  - Improved functional effects (improved bioavailability, reduced variability, food effect, lowest effective dose, well tolerated)
  - Enabling new combinations, routes and dosages (creams, patches, etc.)

☑ **Meet PK 505(b)(2) thresholds**

TherapeuticsMD

RLD = Reference Listed Drug
API = Active Pharmaceutical Ingredient

E+P HT Market Opportunity

- All in-market FDA-approved combination products contain ***non-bioidentical*** progestins
- Today's FDA-approved combination products lack innovation

Product	Progestin	U.S. Sales (est.)	Intl Sales (4)	Company
17β Estradiol + NETA / Drospirenone (Activella / FemHRT / Angeliq / others)	***Non-bioidentical***	**$ 230 mm**(1)(2)		Warner Chilcott / Bayer
Premarin + MPA (Prempro / Premphase)	***Non-bioidentical***	**$ 328 mm** (1)(2)		Pfizer
Estradiol + Progesterone (custom compounded)	**Untested Bioidentical**	**$1,500 mm** (3)		**Not FDA approved**
Total Oral Combination Sales		**$2,058 mm**	**$489 mm**	

TherapeuticsMD

Notes:
(1) PHAST Prescription Monthly by Source Healthcare Analytics.
(2) Based on last twelve months sales through December 31, 2013.
(3) Estimate per Wulf Utian, Executive Director Emeritus and Honorary Founding President of NAMS.
(4) IMS Data

TXMD 2/200mg E2+P *Single* Gel-tab versus Separate 2mg Estrace® tablet + 200mg Prometrium® Capsule

- Evaluation of bioequivalence based on C_{max} and AUC (N=62)



95% Confidence Interval for PK Parameter

Parameter	Point Estimate T/R Ratio	Within Subject Std. Deviation	Upper 95% Confidence Bound
C_{max}	0.88	0.344	-0.040
AUC_{0-t}	0.93	0.409	-0.089

95% Upper Confidence Limit for PK Parameter

Parameter	Point Estimate T/R Ratio	Within Subject Std. Deviation	Upper 95% Confidence Bound
C_{max}	1.16	1.179	-0.785
AUC_{0-t}	1.05	0.956	-0.542

TX 001HR E+P — Phase 3 Study

- **Pivotal Phase 3 clinical trial initiated Q3 '13: The REPLENISH Trial**
- **Designed to enroll 1,750 subjects at ~80 sites**
  - Four active arms (N=400/ arm)
  - Placebo arm (N=150)
- **12-month study with 12 week VMS**
- **Endpoints:**
  - Vasomotor: number and severity of hot flashes (4 week and 12 weeks)
  - Endometrial safety: incidence of endometrial hyperplasia (12 months)

Drug Quality and Security Act

- Signed by President on 11/27/13 *Bill Highlights*

Establishes requirements for traditional compounding pharmacies and larger-scale outsourcing facilities.

Prohibits compounding of essential copies of an FDA approved & marketed drug except in limited circumstances:

Traditional compounding pharmacies may not compound essential copies regularly or in inordinate amounts, or unless there is a change in the compounded drug that produces a significant difference for an individual patient.

Outsourcing facilities may not compound essential copies unless the approved drug appears on the drug shortage list, or unless there is a change in the compounded drug that produces a clinical difference for an individual patient.

Transdermal Development



- **Phase 1 Study Q3 2014**
  - Measure circulating Progesterone alone
  - Measure circulating Estradiol and Progesterone

Transdermal Market Opportunity

Product (Combination E+P)	TRx [1][2]	U.S. Sales (est.) [1][2]	Company
Estradiol/Levonorgestrel (Climara Pro)	129,755	**$ 22.5 mm**	Bayer
Estradiol/Norethindrone Acet (CombiPatch)	408,598	**$ 44 mm**	noven PHARMACEUTICALS, INC.
Total Combination Transdermal Sales	**538,353**	**$ 66.5 mm**	
Product (Estradiol Only)	**TRx [1][2]**	**U.S. Sales (est.) [1][2]**	**Company**
Estradiol (Patch, Gel, Spray) (Alora, Climara, Estraderm, Menostar, Vivelle, Vivell-Dot, Minivelle; Divigel, Elestrin, Estrogel; Evamist)	5,762,725	**$ 692 mm**	Bayer, Watson, Novartis, IVC, Ascend, Meda, Lineage
Total Estradiol Transdermal Sales	**5,762,725**	**$ 692 mm**	

TherapeuticsMD

Notes:
[1] PHAST Prescription Monthly by Source Healthcare Analytics.
[2] Based on last twelve months sales through December 31, 2013.

TherapeuticsMD Core Development Metrics

1. **Estradiol + Progesterone**
   - Well-known chemical entities with defined safety and efficacy therapeutic thresholds

2. **Regulatory Pathway**
   - 505(b)(2) offering more defined, shorter pathway with less efficacy risk than NCE pathway
   - Clear FDA draft guidance requirements for single Phase 3 study

3. **Market**
   - Large, undiscovered, and growing markets with unique dynamics
   - Favorable payor dynamics
   - Drug Quality and Security Act

TherapeuticsMD®

Vulvar / Vaginal Atrophy (VVA)

TherapeuticsMD Core Development Metrics

1. **Compounds**
   - Well-known chemical entities with defined safety and efficacy therapeutic thresholds

2. **Regulatory Pathway**
   - 505(b)(2) offering more defined, shorter pathway with less efficacy risk than NCE pathway
   - Clear FDA draft guidance requirements for single Phase 3 study

3. **Market**
   - Large, underserved, and growing markets with unique dynamics
   - Favorable payor dynamics

Vulvar/Vaginal Atrophy

- **Mechanism: Low Levels of Estradiol impact on the Vagina**
  - Reduction in superficial cells
  - Parabasal cells increase
  - Vagina changes from acidic to basic (increased pH)
  - Most common symptoms: Vaginal Dryness, Dyspareunia, Itching/Irritation, Dysuria, Bleeding with Sexual Activity



Vulvar/Vaginal Atrophy

- **How to Measure Efficacy – FDA Guidance for Phase 3 (12 Weeks)**[1]
  1. Maturation Index
     - Statistical increase in superficial cells
     - Statistical decrease in parabasal cells
  2. Statistical changes in vaginal pH from basic to acidic (decrease pH)
  3. Reduce most bothersome symptoms: Vaginal Dryness, Dyspareunia, Itching/Irritation, Dysuria, Bleeding with Sexual Activity



TherapeuticsMD

(1) FDA Guidance for Industry, *Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Recommendations for Clinical Evaluation* (Jan. 2003)

VagiCap vs. Vagifem – Phase 1 PK Study



Key Points:

- Tmax ~2hours with VagiCap and ~8 hours with Vagifem
- Systemic absorption AUC (0-24 hrs) is 2-3 fold lower with Vagicap relative to Vagifem

TherapeuticsMD

TX 004HR Positive Phase 2 Study

- **48 post-menopausal women with symptoms of VVA**
- **Randomized 1:1 to 10µg dose of TX 004HR or placebo**
  - Self-administered 1x daily for 2-week period
- **Endpoints (2 weeks) based on Phase 3 (12 weeks) study design criteria**
- **As compared to placebo, women treated with TX 004HR showed:**
  - Statistically significant decreases in parabasal cells ($p<0.0001$)
  - Significant increases in superficial cells ($p=0.0002$)
  - Statistically significant decreases in vaginal pH ($p=0.0002$)
  - Significant reduction in the atrophic effects on epithelial integrity and vaginal secretions
  - Not powered for most bothersome symptom (positive trends)

TherapeuticsMD

TX 004HR Phase 2 Study

	Maturation Index (Mean)		Change in pH (Mean)	
	TX 004HR	Placebo	TX 004HR	Placebo
Vagicap 10 ug **Week 2**	44.48	7.08	-0.92	-0.40

TX 004HR Phase 2 Pilot

- N = 50 (mean age 62.3 yrs)
- Randomized 1:1 ratio
- 14 day study

Approved Treatments: Pivotal Clinical Data (Week 12)*

	Maturation Index (Mean)		Change in pH (Mean)		Change in Vaginal Dryness (Mean)	
	Active	Placebo	Active	Placebo	Active	Placebo
Premarin Vaginal Cream (0.3 mg) n=36	27.90	3.00	-1.60	-0.40	-1.10	-0.70
Vagifem (10 ug) n=36	11.10	NA	NA	NA	NA	NA
Vagifem (25 ug) n=36	12.30	NA	NA	NA	NA	NA

*Data from product prescribing information. For reference only. Comparative efficacy cannot be demonstrated without head-to-head clinical studies.

TherapeuticsMD

Leading Estrogen Products

Product Characteristic *	Vagifem	Premarin	Estrace
Design			
Burning		✓	
Discharge	✓	✓	✓
Cream		✓	✓
Quick Dissolution			
Applicator	✓	✓	✓
Placement Issues	✓		

TX 004HR Design Goals

- Eliminate burning sensation
- Not a cream
- Improve ease of use/placement
- Quick dissolution
- Digital insertion/No applicator
- Deliver elegant patient experience

OPERA Survey (n=178); TXV-1301 Survey (n=49)
*Perceived product characteristics reported by health care professionals and patients in separate surveys to identify . Not based on head-to-head clinical comparisons or validated instruments.

VVA U.S. Sales – Currently No Generics

ASD analysis - global market is expected to grow to **$3.1 Billion in 2019**[3]

Product	Compound	TRx	US($mm) Sales[1][2]	WAC Price[1]
Premarin® Cream (Pfizer)	Equine vaginal estrogen	1,703,523	$389	$201[5]
Vagifem® Tablets (Novo Nordisk)	Vaginal Estradiol	1,971,269	$316	$193[5]
Estrace® Cream (Actavis)	Vaginal Estradiol	1,619,744	$284	$152[5]
Total[4]		5,720,550	$1,100 mm	

	2008[1]	2013[1]
Total TRx	5,030,472	5,720,550
Total Sales $	$505,917,525	$1,100,833,171

(1) IMS Prescription Monthly by Source Healthcare Analytics.
(2) Based on last twelve months sales through 12/31/2013.
(3) GlobalData 2/12 report https://www.visiongains.com/news.asp?pr_id=420
(4) Estring & Femring data was excluded due to marginal sales
(5) GoodRx http://www.goodrx.com/ last accessed 4/30/2014

TherapeuticsMD

Estradiol Vaginal Suppository

Phase 2B/3 Study 2014

- **12 weeks**
- **Designed to enroll 150-200 subjects in each arm**
  - Multiple Active Arms (4 mcg, 10 mcg, 25 mcg)
  - Placebo (n=100)
- **Endpoints:**
  - Cell change
  - Lowering of pH
  - Evaluation of Adverse Vaginal Effects (Dyspareunia and Dryness)

TherapeuticsMD

Hormone Therapy Market Opportunity

US Population



TherapeuticsMD

TherapeuticsMD Core Development Metrics

1. **VVA VagiCap**
   - Well-known chemical entities with defined safety and efficacy therapeutic thresholds

2. **Regulatory Pathway**
   - 505(b)(2) offering more defined, shorter pathway with less efficacy risk than NCE pathway
   - Clear FDA draft guidance requirements for single Phase 3 study

3. **Market**
   - Large, underserved, and growing at >20% 5-year CAGR
   - Favorable payor dynamics
   - No generics

Extensive Patent Filings

	Filed	Provisional	Non-Provisional	Issued
U.S.	**27**	10	17	2
Ex-U.S.	**7**			

- Oral combination therapeutics
  - Bioidentical E+P HT combination
  - Natural combination HT and formulations
- Oral solo therapeutics
  - Progesterone formulations
- Vulvovaginal atrophy pessary
- Pipeline applications
- Opera reporting and analysis software

Milestones

2014	E+P Transdermal:	File IND for P and E+P Transdermal	Q2/Q3
	E+P Transdermal:	PK Results for P and E+P Transdermal	Q2/Q3
	E+P Oral:	International Menopausal Society Replenish Trial Poster Session	Q2
	Compounding Market:	Symphony Health Report on BHRT Size of Market	Q3
	Estradiol VagiCap:	Commence Phase 2b/3 VVA Trial	Q3
	Oral Progesterone:	Complete patient enrollment: Spry Trial	Q4
	E+P Oral:	Complete patient enrollment: Replenish Trial	Q4
	IP / Patents	Annual IP Update to Patent Portfolio	Q4
2015	Oral Progesterone	Report Phase 3/Spry Trial Results	Q1
	Estradiol VagiCap:	Complete Patient Enrollment	Q2
	Estradiol VagiCap	Report Phase 3/VVA Trial Results	Q3
	Estradiol VagiCap:	File NDA for TX-003HR in VVA	Q3
	Combination E+P:	Report Replenish Trial results	Q4
	Combination E+P:	File NDA for TX-001HR E+P	Q4

Key Statistics

NYSE MKT: TXMD

Recent market price [1]	$4.05
Shares outstanding [2]	145 million
Market capitalization [1]	$590 million
Cash & equivalents [2]	$45 million
Debt [3]	$0.00 million

TherapeuticsMD

[1] Based upon closing price May 1, 2014
[2,3] As of March 31, 2014

TherapeuticsMD®

Investor Contacts

Dan Cartwright
Chief Financial Officer
TherapeuticsMD, Inc.
561-961-1900
Dan.Cartwright@TherapeuticsMD.com

Lisa M. Wilson
President
In-Site Communications, Inc.
917-543-9932
lwilson@insitecony.com

TherapeuticsMD Corporate History

- Brand Prenatal
- Authorized Generic
- Sales Force

- Early PK data E+P
- CMC Success
- Limited IPO Qualifiers

- Funding
- Combo E+P Dev.

- Funding
- VVA Dev.
- Progesterone Alone

- No Proceeds to Company
- Locked-up sellers sold shares
- Insiders terminate10b5-1 for FY14

Latest Position Statements

British Menopause Society, *2013*
North American Menopause Society, *2012*

- "HRT prescribed before the age of 60 has a favorable benefit/risk profile."
- "Recent evidence suggests that HRT regimens containing **progesterone** can minimize the metabolic impact and reduce the risk of thromboembolism."
- In a large observational cohort study of French teachers, after five years of use estrogen–**progesterone** combination, HRT was found to be associated with a significantly lower relative risk (neutral for 'ever use' of HRT) than for other types of combined HRT (RR 1.7–2.0)."
- "Data from a large observational study suggest that EPT with micronized **progesterone** carries a low risk of breast cancer with short-term use."

TherapeuticsMD

The 2012 Hormone Therapy Position Statement of The North American Menopause Society, Menopause: The Journal of The North American Menopause Society Vol. 19, No. 3, pp. 257/271

The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy, Menopause Int published online May 23, 2013

Experienced Management and Drug Development Team

Management

Robert Finizio
Chief Executive Officer

vitaMed	HT	Corporate		
John Milligan *President*	**Julia Amadio** *Chief Product Officer*	**Dan Cartwright** *Chief Financial Officer*	**Dr. Sebastian Mirkin** *Chief Medical Officer*	**Dr. Joel Krasnow** *Chief Scientific Officer*

Board Members and Early Investors

Tommy Thompson *Chairman* *Former Sec HHS & Gov of Wisc*	**Cooper Collins** *Director*	**Nick Segal** *Director* *Seavest Capital Partners*	**Mario Family Partnership** *Ernest Mario Former CEO of Glaxo*	**Jules Musing** *Former Sr. Executive Johnson & Johnson*

Drug Development Team

- **Julia Amadio and James Pickar, M.D., F.A.C.O.G.**
  - Led development and launch of Prempro®, Premphase®, CombiPatch®, Alesse®, and Crinone®, among others
- **Lisa Rarick, M.D. and Daniel Shames, M.D.**
  - Former division Director of Reproductive and Urologic Products for FDA CDER
- **Fred Sancilio, Ph.D.**
  - Former founder and president of AAI and the innovator of multiple hormone products
- **Marlan Walker, J.D.**
  - Lead Patent Attorney
- **Steve Fontana, J.D.**
  - Author of the original estradiol patents

Proven team with a successful track record of creating shareholder value and developing some of the most successful products in the HT and birth control space